Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.